Outlook Therapeutics OTLK 深 沪
交易中 09-17 11:52:52 美东时间
1.0687
-0.011
-1.05%
华盛通- 最 高1.08
- 今 开1.05
- 成交量 38.08万股
- 最 低 1.05
- 昨 收 1.08
- 总市值 4579.77万
- 52周最高 6.98
- 市盈率 静 --
- 换手率 0.89%
- 52周最低 0.79
- 委 比 -42.69%
- 总股本 4285.37万
- 历史最高 219.20
- 量 比 0.31
- 振 幅 2.78%
- 历史最低 0.79
- 每 手 1
- 风险率 1.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
- **出席活动** Outlook Therapeutics Inc. 将于2025年9月3日在巴黎举行的第25届EURETINA大会上，参加EURETINA Innovation Spotlight活动，演讲题目为"Optimising the treatment of retinal disease"，由CEO Bob Jahr博士主讲。 - **公司简介** Outlook Therapeutics专注于开发眼科用药LYTENAVA™，这是首个获得欧洲和英国批准用于治疗湿性AMD的贝伐珠单抗制剂。在美国该产品正处于临床研究阶段，若获准将是首个用于治疗视网膜疾病的贝伐珠单抗眼科制剂。
09-03 12:35
FDA Issues Complete Response Letter to Outlook Therapeutics
Outlook Therapeutics ( ($OTLK) ) has issued an update. On August 28, 2025, Outl...
09-03 05:32
Outlook Therapeutics Requests Type A Meeting with FDA
Outlook Therapeutics, Inc. has submitted a Type A Meeting request to the FDA to discuss the recent Complete Response Letter regarding the resubmitted BLA for ONS-5010, an investigational ophthalmic formulation of bevacizumab for treating wet AMD. The FDA acknowledged the NORSE TWO pivotal trial met safety and efficacy endpoints but requested additional confirmatory efficacy data. The company believes the meeting will provide clarity on the FDA’s ...
09-02 12:35
Guggenheim Downgrades Outlook Therapeutics to Neutral
Guggenheim analyst Eddie Hickman downgrades Outlook Therapeutics (NASDAQ:OTLK) from Buy to Neutral.
08-30 00:51
FDA Declines Outlook Therapeutics' Wet AMD Drug Application In Present Form
FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLAOutlook Therapeutics plans to work with FDA to address the Agency's issuesCompany to host a conference call and webcast today, August 28th at 8:30 AM
08-28 18:33
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
Outlook Therapeutics announced the FDA issued a complete response letter (CRL) for its ONS-5010 BLA resubmission, citing a lack of substantial evidence of effectiveness. The company plans to meet with the FDA to address the deficiency and explore potential approval pathways. Outlook Therapeutics also intends to expand into additional European markets, as LYTENAVA, its bevacizumab product, has received marketing authorization in the EU and UK for ...
08-28 10:30
Why MongoDB Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket
Shares of MongoDB, Inc. (NASDAQ:MDB) rose sharply in pre-market trading after t...
08-27 18:05
美股牛股 | 迅雷绩后上演翻倍行情！投资影石创新浮盈超50亿；OpenDoor隔夜大涨19%
迅雷绩后上演翻倍行情！投资影石创新浮盈超50亿；OpenDoor隔夜大涨19%，此前获知名加密货币投资者买入>>
08-19 19:53
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-18 19:50
Navigating Trade Turbulence: Outlook Therapeutics’ Struggle with Global Trade Policies
Outlook Therapeutics (OTLK) has disclosed a new risk, in the Capital Markets ca...
08-16 14:00
